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Abstract: 
 
Nowadays computational chemistry has become a corner stone in the field of drug and 
prodrug design. Tranexamic acid which is a well known antifibrinolytic agent. Though, the 
drug suffers from a short half life and a low bioavailability as a result of being an amino 
acid derivative. 
A new derivative of tranexamic acid with a higher bioavailability and a controlled release 
rate seems an attractive alternative. Designing tranexamic acid prodrugs via the 
computational pathway is a great pre step before beginning any experimental work. It gives 
us a hint on the expected experimental results while saving time and money. 
In this thesis six Tranexamic acid prodrugs were designed depending on Kirby’s proton 
transfer enzyme model. Calculations were made using the DFT method at B3LYP/6-31G 
(d,p) level. Calculations were run in the gas phase and in a dielectric constant of 79.38. 
From the  DFT calculation results it was revealed that the rate of a proton transfer in 
processes Tranexamic acid ProD1-ProD6 is largely dependent on the geometric variations 
of the reactant (GM) mainly the distance between the two reactive centers, rGM, and the 
angle of attack α. It was found that systems with low rGM and high α values in their global 
minimum structures, such as ProD1, ProD2 and ProD3 exhibit much higher rates (lower 
∆G‡) than these with high rGM and low α values, such as ProD4-ProD6. Thus, it is 
recommended that Tranexamic acid ProD1-ProD3 should further precede into in vitro and 
in vivo testing. 
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Chapter one: 
_____________________________________________________________ 
Introduction 
1.1 Computational chemistry background 
 
Computational chemistry is a branch of chemistry that uses equations encapsulating the 
behavior of matter on an atomistic scale. Equations are solved computationally to calculate 
structures and properties of molecules in order to explain or predict chemical phenomena. 
In the recent few decades computational chemistry had put a fingerprint in the field of drug 
and prodrug design. Many computational methods are being used in the design and 
production of a wide variety of chemical compounds. Besides, they enable us to unravel 
the exact mechanism of reactions [1]. Contemporary drug design relies on these 
computational approaches for predicting experimental results. 
Chemical computational methods are divided into two major subdivisions: Molecular 
Mechanics (MM) and Quantum Mechanics (QM) the latter includes: Density Functional 
Theory (DFT), ab initio and semi-empirical methods. 
 
1.1.1. Quantum mechanics methods 
1.1.1.1. Ab initio method [1] 
 
Ab initio method refers to quantum chemistry; this term was first used by Robert Parr et al 
[1].  
Ab initio molecular orbital methods include: HF, G1, G2, G2MP2, MP2 and MP3 which 
are based on rigorous use of the Schrodinger equation with a number of approximations. 
3 
 
Ab initio calculation is an important tool for investigating functional mechanisms of 
biological macromolecules based on their three-dimensional and electronic structures. 
Accordingly, isolated models of interesting parts of proteins (e.g., active sites) have been 
studied using ab initio calculations method.  
Limitations of using ab initio method include treating only small-sized molecules, high 
cost and consumption of computer time, memory. Another disadvantage is ignoring 
proteins and solvents surrounding the catalytic centers, this implies that ab initio 
calculations using only the catalytic centers have difficulty in the understanding of 
biological systems. 
1.1.1.2 Semi empirical method:
 
 
This method is based on Hartree-Fock Formalism but with many approximations and 
obtains some parameters from empirical data. Among the most used semi-empirical 
methods are MINDO, MNDO, MINDO/3, AM1, PM3 and SAM1. The semi-empirical 
methods have afforded vast information for practical application [2-5].  
Semi empirical methods are considered beneficial for treating large molecules were the use 
of full Hartree-Fock Formalism is very expensive. It is much faster than ab initio and 
allows an inclusion of electron correlation effects. Calculations of molecules exceeding 60 
atoms can be done using such methods. However, results can be very wrong if the 
molecule being computed is not similar enough to the molecules in the database used in 
parametrizing the method. 
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1.1.1.3 Density functional theory (DFT): 
 
DFT is the most popular and commonly used method in physics and chemistry to 
investigate the electronic structure (principally the ground state) of many-body systems, in 
particular atoms, molecules and the condensed phases. 
With this theory, the properties of a many-electron system can be determined by using 
functionals, that is, functions of another function, which in this case is the spatially 
dependent electron density. Hence the name DFT comes from the use of functionals of the 
electron density. It is used to calculate structures and energies for medium size molecules 
(30-60 atoms) [6]. 
1.1.2 Molecular mechanics (MM): 
 
MM is a mathematical approach used for the computation of structures, energy, dipole 
moment and other physical properties and is widely used in calculating many diverse 
biological and chemical systems such as proteins, large crystal structures and relatively 
large solvated systems. However, this method is limited by the determination of parameters 
such as the large number of unique torsion angles present in structurally diverse molecules 
[7]. 
To overcome these difficulties, QM/MM calculations are utilized, in which the system is 
divided into QM and MM regions, where QM regions correspond to active sites to be 
investigated, and they are described quantum mechanically.MM regions correspond to the 
remainder of the system and are described molecular mechanically. The pioneer work of 
the QM/MM method was accomplished by Warshel and Levitt [8], and since then, there 
has been much progress on development of QM/MM algorithm and applications to 
biological systems [9, 10]. 
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1.2 Tranexamic acid background: 
 
Tranexamic acid; Trans-4-(aminomethyl)cyclohexanecarboxylic acid (Figure 1) , is a 
white crystalline powder. With a molecular formula of (C8H15NO2) and a molecular weight 
of 157.21 g/mol.   
 
 
Figure 1: Chemical structure of tranexamic acid. 
 
Tranexamic acid is a synthetic lysine amino acid derivative, which exerts its effects by 
competitively inhibiting the activation of plasminogen to plasmin, thereby inhibiting fibrin 
degradation. The drug use is considered attractive due to its minimal effect on blood 
clotting parameters. It is eight times more efficient than the older antifibrinolytic ε-
aminocaproic acid [11]. 
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1.2.1 Tranexamic acid uses: 
 
Since it was introduced into clinical practice over 30 years ago, Tranexamic acid has been 
used for a wide variety of clinical conditions in which antifibrinolytic therapy has been 
deemed potentially beneficial. 
Tranexamic acid was originally used in order to prevent excessive hemorrhage in 
hemophilia patients and to reduce the need for replacement therapy following tooth 
extraction. 
In the recent years its use have expanded beyond hemophilia patients and tooth extracts to 
become an important agent which is used to decrease mortality rates due to bleeding in 
trauma patients which was proved by CRASH-2 clinical study [12]. Also, it reduces blood 
loss in women who undergo C- section, the need for intra-operative blood transfusion 
during heart, hip and knee replacement and liver transplant surgeries [13].  
It is used to reduce blood loss in excessive menstrual bleeding [14]; the recommended 
dosage of tranexamic acid in this situation is two 650mg tablets three times daily for five 
days [15]. It is used orally to treat melasma; a hypermelanosis disease that occurs in Asian 
women [16]. 
Finally, it was found that tranexamic acid is effective in inhibiting urokinase in urine, so it 
has been used for treating severe hematourea in patients with chronic renal impairment 
who poorly respond to conventional therapies [17].  
Recent studies have proved the ability of tranexamic acid to inhibit ultraviolet radiation 
induced pigmentation, thus it can be used topically as a bleaching agent [18]. 
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1.2.2 Tranexamic acid pharmacokinetics: 
 
Oral bioavailability of tranexamic acid is thirty five percent. The drug absorption after oral 
administration is not affected by food and he drug reaches C max in 3 hours.  The initial 
volume of distribution is about 9 to 12 L. Ninety-five of the drug is excreted unchanged in 
the urine after intravenous administration. The plasma protein binding of tranexamic acid 
is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding 
to plasminogen [19-23].     
The drug crosses the Blood Brain Barrier (BBB) and placenta with minimal excretion in 
breast milk. It is not detectable in saliva after oral administration [24-26]. The use of 
tranexamic acid mouthwash (5% w/v) results in plasma drug concentrations below 2 mg/L 
[27].  
 
1.2.3 Tranexamic acid pharmacodynamics: 
 
Tranexamic acid exerts its antifibrinolytic effect by blocking lysine binding sites on 
plasminogen molecules and thereby inhibiting the interaction of plasminogen and the 
heavy chain of plasmin with lysine residues on the surface of fibrin. Although plasmin can 
still be formed under these circumstances, it is unable to bind to and degrade fibrin [28, 
29]. 
Tranexamic acid is 6 to 10 times more potent in terms of binding to plasminogen/plasmin 
than ε-aminocaproic acid (EACA) [30].The drug has no effect on coagulation parameters. 
Concurrent administration of heparin does not influence the activity of Tranexamic acid 
[31]. 
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1.2.4 Tranexamic acid associated side effects: 
On general Tranexamic acid is well tolerated; nausea and diarrhea are the most common 
adverse events [32]. Increased risk of thrombosis with the drug has not been demonstrated 
in clinical trials.  
The low bioavailability and short half-life of the drug (approximately 2 hours), which lead 
to poor patient compliance, had inspired us to search for a better alternative of the parent 
drug. 
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1.3 Problem statement: 
 
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality, resulting in 
100,000 deaths every year. PPH is usually managed by uterotonic agents including 
oxytocin and misopristol are used to reduce blood loss, and by replacing fluids and blood 
in severe cases [33, 34]. 
Providing blood for these patients is considered a problem in the third world countries, so 
an alternative oral agent to reduce blood loss such as Tranexamic acid is a crucial need in 
these developed countries. 
Since Tranexamic acid is an amino acid derivative with a log P (partition coefficient) value 
of (-1.6), it undergoes ionization in physiologic environments and its oral bioavailability is 
low (35%) due to inefficient absorption through membranes resulting in the need for 
frequent administration leading to an increase in side effects and reducing patient 
compliance [34]. 
Hence, there is a necessity to design and synthesize relatively more lipophilic Tranexamic 
acid prodrugs that can provide the parent drug in a controlled release manner which 
mightresult in better clinical outcome, more convenient dosing regimens and potentially 
less side effects than the original medication. 
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Figure 2: Conversion of Tranexamic acid prodrugs to their parent drug, Tranexamic Acid. 
 
Nowadays the contemporary drug synthesis relies on computational approaches. Thus 
instead of starting the experimental work computational calculations are done for each 
drug giving a hint on the expected experimental results. 
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1.4 Thesis Objectives 
1.4.1General objectives: 
 
The main objective of this thesis was to complete the design of six Tranexamic acid 
prodrugs with a higher bioavailability and with the ability to release Tranexamic acid in the 
body in a controlled manner depending on solely intramolceular reactions (based on 
Kirby’s enzyme model of intramolecular proton transfer using a variety of different 
molecular orbital and molecular mechanics). 
1.4.2 Specific objectives: 
 
To apply Kirby’s enzyme model calculations on the design of six Tranexamic acid 
prodrugs. These prodrugs should fulfill the following properties: 
1- To be able to release Tranexamic acid in a controlled manner. 
2- To be able to increase the bioavailability of the drug. 
3- To assure that the prodrug and the attached inactive linker is a safe manner. 
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1.5. Research questions: 
 
 Would the DFT methods be capable of producing reaction rates similar to that 
obtained by Kirby? 
 Do the DFT calculations offer good methods for designing of Tranexamic acid 
prodrugs that have the potential to provide the active drug with higher 
bioavailability and be cleaved in physiological environments to furnish the active 
drugs and a non-toxic moiety? 
 How would the rate of release be affected by the surrounding environment? 
 Can we provide a successful alternative to Tranexamic acid with higher 
bioavailability and fewer side effects? 
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Chapter Two 
_____________________________________________________________ 
Literature Review  
 
2.1 Enzymes: 
 
Enzymes are protein structures with crucial functions existing in our bodies. Their 
mechanism of action and interactions between enzymes and substrates had been explored 
extensively. The rate of a certain process is increased from 10
10
 to 10
18 
fold in the presence 
of enzymes when compared with their non-enzymatic bimolecular counterparts [35]. 
The majority of prodrugs are amides or esters which get activated by enzymatic action.  
Trypsin, chymotrypsin, elastase, carboxypeptidase, and aminopeptidase are considered the 
major enzymes responsible for amide prodrug activation. On the other hand, paraoxonase, 
carboxylesterase, acetylcholinesterase and cholinesterase are the major enzymes 
responsible for ester prodrugs activation. CYP450 enzymes are also engaged in prodrug 
activation [36]. 
One can control reaction rate by making slight changes in the structural features of enzyme 
model, thus, offering a wide range of reaction rates from 1 to 10
15
 folds [37]. Such a broad 
range enables prodrug design that is independent of enzymatic activation with varying 
release rates according to the main aim of the design. 
Most of the existing prodrugs contain an ester or an amide bonds that occurs as a result of 
derivatizing a hydroxyl, carboxyl, or amine group present in the parental drug. Cleavage of 
these bonds occurs mainly by hydrolysis and oxidation.  The main problem of enzymatic 
activation of prodrugs is unpredictable conversion rates which are affected by various 
factors such as: polymorphism, age, health, smoking and gender [38–40]. 
15 
 
 Both, enzymes and intramolecular processes are similar in that the reacting centers are 
held together (covalently with intra molecular systems, and non-covalently with enzymes) 
[41]. 
Mechanisms of some enzyme models that have been used to gain a better understanding of 
enzyme catalysis have been recently investigated and utilized by Karaman’s group for the 
design of novel prodrug linkers [42-48].  
 
2.2 Prodrugs: 
 
In 1958 the term prodrug was first introduced by Albert et al. Prodrugs are reversible 
derivatives of drug molecules designed to overcome certain pharmaceutical, 
pharmacokinetic and pharmacodynamic problems, such as low oral absorption, lack of site 
specificity, insufficient chemical stability, poor solubility, toxicity, and unacceptable 
taste/odor [49]. 
 
Prodrug design has been more popular and successful than designing a novel drug. 
Prodrugs represent approximately 10% of the world’s marketed medications and 20% of 
all small molecular medications that had been approved between 2000 and 2008 [50]. 
Prodrugs can be designed as targeted, chemically activated or intramolecularly activated 
prodrugs. Targeted prodrugs are designed to takes advantage from the physiological 
environment by attaching the drug to a moeity that have carrier/enzyme specifity. Targeted 
prodrugs need a wide knowledge of the functional and molecular characteristics of 
particular enzymes or carriers. Fora successful prodrug targeting the following 
requirements must befulfilled as suggested by Stella and Himmelstein: the drug must be 
16 
 
transported to its site rapidly, cleaved there selectively and retained at its site of action for 
a reliable time [51].  
Intramolecularly activated prodrugs does not depend on enzymatic activation, they are 
solely dependent on the rate limiting step of the intramolecular reaction. These prodrugs 
are designed depending on calculations using molecular orbital (MO) and molecular 
mechanics (MM).  
2.2.1. Conventional prodrug classification: 
 
Prodrugs are classified based on the type of carriers and derivatization into: 
 
(1) Carrier-linked prodrugs, in which the promoiety is covalently linked to the active drug 
but it can be easily cleaved by enzymes (such as an ester or labile amide) or non-
enzymatically to provide the parent drug [52, 53].  
 
(2) Bioprecursors which are chemical entities that are metabolized into new compounds 
that may be active or further are metabolized to active metabolites (such as amine to 
aldehyde to carboxylic acid). In this prodrug type there is no carrier but the compound 
should be readily metabolized to induce the necessary functional groups [54-56].   
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2.2.2. Prodrug approach associated disadvantages: 
 
Although the prodrug approach is very popular, yet there are several challenges to be 
faced:  
 Esterase hydrolysis: the most common approaches for prodrug design are aimed at 
prodrugs undergoing in vivo cleavage to the active drug by catalysis of  hydrolyses 
such as peptidases, phosphates, and carboxyl-esterases[57].  Several hydrolyase 
activated prodrugs have bioavailability around 50% because of their premature 
hydrolysis during the absorption process in the enterocytes of the gastrointestinal 
tract [57]. Hydrolysis inside the enterocytes releases the active drug, which in most 
cases is more polar and less permeable than the prodrug and is more likely to be 
effluxes by passive and carrier-mediated processes back into the lumen than to 
proceed into blood, therefore limiting oral bioavailability. 
 Bioactivation by cytochrome P450 enzymes: The CYP450 superfamily enzymes 
play a major role in drug metabolism that accounts for approximately 75% of 
enzymatic metabolism of drugs. The genetic polymorphisms of prodrug-activating 
P450s contribute substantially to the variability in prodrug activation and thus to 
the efficacy and safety of drugs using this bioactivation pathway [58,59]. 
 
To overcome such problems of the traditional prodrugs, the novel prodrug approach for 
drugs that contain hydroxyl, phenol, or amine groups is considered a great alternative.  
These drugs are designed based on intramolecular processes (enzyme models), that were 
advocated to assign the factors playing dominant role in enzyme catalysis. Prodrug design 
is based on computational calculations, using different molecular orbital and molecular 
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mechanics methods, and correlations between experimental and calculated rate values for 
some intramolecular processes.  
Such approach does not require enzyme catalysis for the intra-conversion of a prodrug to 
its active parent drug. The release rate of the active drug is determined only by the factors 
playing dominant role in the rate limiting step of the intra-conversion process. Using this 
approach might have a potential to eliminate all disadvantages associated with prodrug 
interconversion by enzymes[60]. 
In the past five decades proposals have been made from attempts to interpret changes in 
reactivity versus structural variations in intramolecular systems. Many organic chemists 
and biochemists, such as Pandit and Bruice [61,62], Koshland[63],Kirby [64] and Menger 
[65-70], have been extensively engaged in studying a variety of intramolecular systems 
(enzyme models) for achieving a better understanding of biochemical enzyme catalysis. 
As was mentioned previously, Karaman et al. had been engaged in the investigation of the 
mechanisms of some intramolecular processes. His group has been researching the 
mechanistic pathways of some intramolecular processes that was mentioned above, to be 
utilized in designing prodrugs for common drugs that suffer from poor bioavailability 
or/and have bitter sensation [71-77]. They have designed a variety of prodrugs that are 
independent of enzymatic catalysis for active drug release; instead, they are completely 
dependent on intramolecular chemical reactions for their release. This is because prodrugs 
that depends on enzyme catalysis are vulnerable and unpredicted because there are many 
intrinsic and extrinsic factors that can affect their bioconversion. For example, the activity 
of many prodrug activating enzymes may be flocculated due to genetic polymorphisms, 
age-related physiological changes or drug interactions, leading to adverse 
pharmacokinetics, pharmacodynamics and clinical effects. In addition, there are wide 
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interspecies variations in both the expression and function of most of the enzyme systems 
activating prodrugs which could lead to serious challenges in the preclinical optimization 
phase [78]. 
Utilizing DFT and ab initio molecular orbital calculation methods, Karaman et al. have 
studied intramolecular processes (enzyme models) to assign the factors affecting the rate-
limiting step and playing dominant roles in governing the reaction rate. Among these 
enzyme models are: 
(1) Proton transfer between two oxygens in Kirby acetals and between nitrogen and 
oxygen in Kirby’s enzyme models [79]. 
(2) Intramolecular acid-catalyzed hydrolysis in Kirby’s maleamic acid amide 
derivatives [44, 47-48]. 
(3)  Proton transfer between two oxygens in rigid systems as investigated by 
Menger[64-67] and Cohen [80-82]. 
(4) SN2-based-cyclization reactions of di-carboxylic semi-esters to yield anhydrides as 
studied by Bruice [61, 62]. 
(5) Intramolecular SN2-based ring-closing reactions as researched by Brown and 
Mandolini[83,84].  
From Karaman’s studies on intramolecularity it was concluded that: 
 Rate enhancement in intramolecular processes is a result of both entropic and 
enthalpy effects. In the cases by which enthalpy effects were predominant such as 
ring-closing and proton transfer reactions proximity or/and steric effects were the 
driving force for the rate accelerations. 
 The distance between two reactive centers plays an important role too. If the 
distance exceeds 3Å an intermolecular reaction is preferred and vice versa. 
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 In SN2-based ring-closing reactions leading to three-, four- and five-membered 
rings the gem-dialkyl effect is more dominant in processes involving the formation 
of an unstrained five-membered ring, and the need for directional flexibility 
decreases as the size of the ring being formed increases. 
 An efficient proton transfer between two oxygens and between nitrogen and 
oxygen in Kirby’s acetal systems were affordable when a strong hydrogen bonding 
was developed in the products and the corresponding transition states leading to 
them.  
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2.3. Intermolecular and intramolecular reactions: 
 
Since we lay a complete dependence on intramolecular forces for the release of active drug 
from our designed prodrugs, a brief explanation on the difference between intra and 
intermolecular forces and their subdivisions had been clarified. 
2.3.1. Intermolecular forces: 
 
Intermolecular forces are defined as the forces that determine the properties of substances. 
They are particularly important in terms of how molecules interact together and form 
biological organisms and life [85]. 
2.3.1.1. Intermolecular forces include the following types of bonding: 
 
 Strong ionic attraction; electrostatic attraction between oppositely charged ions. 
This type constitutes the major type of bonding in ionic compounds. 
 Intermediate dipole-dipole forces; substances whose molecules have dipole 
moment, have higher melting point or boiling point than those of similar molecular 
mass with no dipole moment. 
 Weak London dispersion forces or van der Waal's force: these forces always 
operate in any substance. The force arises in from induced dipole and the 
interaction is weaker than the dipole-dipole interaction. In general, the heavier the 
molecule, the stronger the van der Waal's force of interaction; boiling points of 
inert gases increase as their atomic masses increase due to stronger Landon 
dispersion interactions.  
 Hydrogen bonding; It is a special type of dipole-dipole attraction that occurs when 
a hydrogen atom bonded to an atom with high electronegativity (such as N,O,F) 
exists in the vicinity of another electronegative atom with a lone pair of electrons. 
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 Covalent bonding; covalent is really intramolecular force rather than intermolecular 
force. However, some solids are formed due to covalent bonding example: silicon, 
quartz etc.. These solids are hard, brittle, and have high melting points. Covalent 
bonding holds atoms tighter than ionic attraction.  
 Metallic bonding; forces between atoms in metallic solids belong to another 
category. Valence electrons in metals are rampant. They are not restricted to certain 
atoms or bonds. Rather they run freely in the entire solid, providing good 
conductivity for heat and electric energy. This behavior of electrons gives special 
properties such as ductility and mechanical strength to metals. 
2.3.2. Intramolecular forces: 
Intramolecular forces are defined as the forces that hold atoms together making up a 
molecule. They include all types of chemical bonds and are considered much more 
stronger than the intermolecular ones[86]. 
2.3.2.1. Intramolecular reactions: 
 
In these reactions the functional groups bring together on the same molecule resembling 
what occurs when an enzyme brings together the same functional groups in its active site. 
From their ab initio calculations Karaman and Menger had demonstrated that when the 
distance between the two reacting centers is about 2.4  , an intramolecular reaction is 
more preferable. However, when the distance exceeds 3  , the reaction usually proceeds 
via the intermolecular pathway [87]. 
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Chapter Three: 
_____________________________________________________________ 
Computational (Design) section  
3.1. Computation programs: 
 
Calculations software used in the accomplishment of thesis calculations were: 
3.1.1. Argus lab. 
3.1.2. Gaussian. 
3.1.3. Molden. 
3.1.1. Argus lab: 
 
A popular program that is commonly used for molecular modeling, graphic, and drug 
design. It is available for free on the World Wide Web. It is used to draw and edit 
molecular structures, visualize them in three dimensions, rotate, translate and modify 
atoms and molecules, and more importantly run Molecular Mechanics and semiempirical 
Quantum Mechanical calculations. 
Argus lab is used for optimizing geometries of the wanted molecules, it allows for 
calculating Molecular Mechanics (UFF/Amber force fields) and QM semi-empirical 
(INDO, AMI, PM3) calculations such as evaluating single-point energies for fixed 
geometry, geometry optimization in the ground state, and more importantly obtain UV-VIS 
spectra of delocalized systems in gas phase and in several dielectric environments [88]. 
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Argus lab writes its own format of molecule file like, .xml, but also it can write xyz files 
that are used as an input for other calculation programs such as Molden. Nevertheless, 
Argus lab leaves a lot of temporary files that need further managing. 
Working with Argus lab is kind of easy, at first we click at the Argus lab item, after the 
Argus lab screen has opened click on new, or click on open for a previously saved file. 
Our policy is to run AM1 and UFF calculations. It is noteworthy to save the molecule in 
two names one before any modification on the molecule and the other after geometrical 
optimization.  
After completing the work with Argus lab click on file then exit [89]. 
 
3.2.2. Gaussian2009: 
 
Gaussian2009 was first introduced in 1970 by John Pople and it was named Gaussian70. 
Pople’s had received a noble prize in 1998 for his work in the field of quantum 
computational chemistry.Gaussian09 is the latest version of this program and it is also 
freely downloadable. 
Gaussian predicts the energies, molecular structures, and vibrational frequencies of atomic 
or molecular systems, along with numerous molecular properties in the gas or liquids phase 
depending on the basis of the classical quantum mechanics. It can be used by chemists, 
chemical engineers, biochemists, physicists and others scientist for research in established 
and emerging areas of chemical interest. It allows performing virtual chemistry with a 
reasonable cost and saving much experimental time in the laboratory [90]. 
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Experimental chemists can use it to study molecules and reactions of definite or 
potential interest, including both stable species and those compounds which are difficult or 
impossible to observe experimentally (short-lived intermediates, transition structures and 
so on)[91]. AM1, PM3, MINDO/3, MNDO, HF, DFT, MP2 and MP3 in all possible 
different levels can be run using Gaussian 09. 
Steps for using Gaussain09: 
At first, an input file is created either by hand or via molden software. 
•By hand: using local editor (VI, emacs and nedit).  
Using molden: 
 Viewing output files from files run in Gaussian 09. Further, input files for use in 
Gaussian 09 can be generated using Molden program. 
 Dissecting the output file:the Z-matrix represents how the software knows the 
molecular geometry (structure). Notice that the molecule has no charge and a 
multiplicity of 1 (all paired electrons). The structure is also represented as a more 
standard xyz coordinate system. The distance matrix shows the distance of each 
atom from the other atoms, in units of angstroms. 
3.3.3. Molden: 
 
Molden is a package for displaying Molecular density from ab initio packages GAMESS-
UK, GAMESS-US, GAUSSIAN and the Semi-Empirical packages. 
 
Molden is used as a standardizing method since it interprets information from all of these 
programs into its own format. 
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The Molden program can also be used as a visual Z-matrix molecule editor, thereby 
allowing users to create the molecule of their choice and being able to save the geometry in 
the Molden format[92]. 
 
It is capable of displaying Molecular Orbitals, the electron density and the Molecular 
minus Atomic density. Either the spherically averaged atomic density or the oriented 
ground state atomic density can be subtracted for a number of standard basis 
sets.  Molden supports contour plots, 3-d grid plots with hidden lines and a combination of 
both.  
It can write a variety of graphics instructions; postscript, XWindows, VRML, povray, 
OpenGL, tekronix4014, hpgl, hp2392 and Figure. Both X-windows and OpenGL versions 
of Molden are also capable of importing and displaying of Chemx, PDB, and a variety of 
Mopac/Ampac files and lots of other formats. Molden also can animate reaction paths and 
molecular vibrations. It can calculate and display the true or Multipole Derived 
Electrostatic Potential and atomic charges can be fitted to the Electrostatic Potential 
calculated on a Connolly surface. Atom typing can be done automatically and interactively 
from within Molden, as well as running optimization jobs. Molden has a powerful Z-
matrix editor which gives full control over the geometry and allows you to build molecules 
from scratch, including polypeptides. Molden was also submitted to the QCPE 
(QCPE619), although the X-windows version is considerably running behind on the 
current one [93]. 
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3.2 Calculation methods: 
 
3.2.1 Tranexamic acid prodrugs: 
 
The Becke three-parameter, hybrid functional combined with the Lee, Yang and Parr 
correlation functional (B3LYP), were employed in the calculations using DFT. All 
calculations were carried out using the quantum chemical package Gaussian-2009. 
Calculations were carried out based on the restricted Hartree-Fock method. The starting 
geometries of all calculated molecules were obtained using the Argus Lab program and 
were initially optimized at the AM1 and HF/6-31G levels of theory, followed by 
optimization at the B3LYP/6-31G(d,p). Total geometry optimizations included all internal 
rotations. 
Second derivatives were estimated for all 3N-6 geometrical parameters during 
optimization. An energy minimum (a stable compound or a reactive intermediate) has no 
negative vibrational force constant. A transition state is a saddle point which has only one 
negative vibrational force constant. 
Transition states were located first by the normal reaction coordinate method where the 
enthalpy changes were monitored by stepwise changing the inter-atomic distance between 
two specific atoms. The geometry at the highest point on the energy profile was re-
optimized by using the energy gradient method at the B3LYP/6-31G(d,p) level of theory.  
Full optimization of the transition states was accomplished after removing any constrains 
imposed while executing the energy profile. The activation energies obtained from the 
DFT for all molecules were calculated with and without the inclusion of water (dielectric 
constant of water, 78.39).  
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The calculations with the incorporation of a water molecule were performed using the 
integral equation formalism model of the polarizable continuum model. In this model, the 
cavity is created via a series of overlapping spheres. The radii type employed was the 
United Atom Topological Model on radii optimized for the PBE0/6-31G (d) level of 
theory. 
 
 
Chart 1: Schematic representation of the reactants in the proton transfers of Tranexamic acid.  GM 
is the global minimum structure, rGM is the O—H distance in the GM. α, is the angle of attack 
(hydrogen bonding) O1-H7-O6 in the GM. 
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Chapter Four: 
_____________________________________________________________ 
Results and Discussion 
 
Continuing Karaman’s work on the utilization of enzyme models as potential carriers for 
drugs containing amine and hydroxyl groups, and relying on Kirby’s enzyme model of the 
proton transfer reactions in the acid-catalyzed hydrolysis of N-alkyl maleamic acids 1-7 
(Figure 2); We have proposed six Tranexamic acid prodrugs, Tranexamic prodrugs ProD1- 
ProD6 (Figure 3). Our strategy in prodrug design was by replacing the N-methyl amide 
group in 1–7 of Kirby’s N-alkylmaleamic acid (Figure 4) with a Tranexamic acid entity, as 
shown for ProD1-ProD6 in (Figure 2). 
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Figure 3: Acid-catalyzed hydrolysis of 1-7 N-alkylmaleamic acids. 
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Figure 4: Structural formula of the proposed Tranexamic acid ProD 1-ProD 6. 
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As shown in Figure 4, Tranexamic acid prodrugs, ProD1-ProD6 have a carboxylic group 
(hydrophilic moiety) and a lipophilic moiety (the rest of the prodrug), where the 
combination of both moieties secures a relatively moderate HLB. 
Tranexamic acid itself will exist primarily as an ionized entity in most of the physiological 
environments (pH 1- 8.0) (Figure 5).  However, our proposed prodrugsProD1-ProD6 will 
equilibrate between the ionic and the free acid forms (Figure 5) especially in the 
physiological pH environment of 5.5-6.8 (intestine). 
 
Figure 5: The ionization of Tranexamic acid and Tranexamic acid prodrug at the 
physiological environment. 
As a result, it is expected that these designed prodrugs will improve the pharmacokinetic 
parameters of the parent drug including its bioavailability due to neutralizing the ionization 
of the amine group which results in the oral absorption improvement. In addition, these 
prodrugs may be used in different dosage forms (i.e. enteric coated tablets, topical use and 
etc.) because of their potential solubility in organic and aqueous media due to the ability of 
the carboxylic group to be converted to the corresponding carboxylate anion in a 
physiological pH of around 6.0. 
It should be emphasized that at pH 5.5-6.5 (SC, skin, mouth cavity and intestine 
physiologic environments) the carboxylic group of the prodrugs will equilibrate with the 
corresponding carboxylate form (Figure 5). Subsequently, the free acid form will undergo 
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proton transfer reaction (rate limiting step) to yield the antifibrinolytic drug, tranexamic 
acid, and the inactive linker as a by-product (Figure 4).  
From his study on Kirby’s enzyme model of acid catalyzed proton transfer in seven N-
alkylmaleamic acid derivatives, Karaman have revealed that the rate limiting step depends 
on the reaction media; in the gas phase the rate limiting step was found to be tetrahedral 
intermediate formation while, in the water phase the rate limiting step was tetrahedral 
intermediate collapse.  
Also, He had revealed that other factors significantly affect the acid-catalyzed hydrolysis 
efficiency including; angle of attack(α), difference between the strain energies of the 
intermediate and product, as well as between the intermediate and reactant and the strain 
energy (EsINT), and finally the distance between the hydroxyl oxygen of the carboxylic 
group and the amide carbonyl carbon(rGM). 
DFT calculations made by Karaman have proved that the acid catalyzed reaction proceeds 
in three consecutive steps: 
(1) Proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen. 
(2) Nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon. 
(3) Dissociation of the tetrahedral intermediate to provide products (Figure 6). 
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Figure 6: Proposed mechanism for the acid-catalyzed hydrolysis of N-alkylmaleamic acids. 
 
In this section, we report DFT at B3LYP 6-31G (d,p) level calculations of ground state and 
transition state structures, vibrational frequencies, and reaction trajectories for 
intramolecular proton transfer in Tarnexamic acid prodrugs ProD1- ProD6. 
 
Computations were directed toward elucidation of the transition and ground state structures 
for the acid-catalyzed hydrolysis of tranexamic acid ProD1– ProD6 in the gas phase, 
dielectric constant of water (79.38). It is expected that the stability of the chemical entities 
will be different in the gas phase compared to that in water phase. 
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4.1 General Consideration 
 
Because the energy of a carboxylic acid amide molecule is strongly dependent on its 
conformation and the latter determines its ability to be engaged in intramolecular hydrogen 
bonding, we were concerned with the identification of the most stable conformation 
(global minimum) for each of prodrugs ProD1– ProD6 calculated in this study. This was 
accomplished by 360° rotation of the carboxylic group about the bond C6-C7 (i.e., 
variation of the dihedral angle O1C7C6C5, Chart 1), and 360° rotation of the carbonyl 
amide group about the bond C4-C5 (i.e., variation of the dihedral angle O3C4C5C6) in 
increments of 10° and calculation of the conformational energies (Chart 1). 
  
 
In the DFT calculations for tranexamic acid ProD1– ProD6, two types of conformations in 
particular were considered: one in which the amide carbonyl is syn to the carboxyl group 
and another in which it is anti. The global minimum search for tranexamic ProD1- ProD6 
revealed that ProD1, ProD2 and ProD3 exist in the syn orientation while ProD4-ProD6 
exists in the anti-orientation (Chart 1). 
 
4.2. Optimized geometries of the entities involved in the proton transfers 
of tranexamic acid ProD1- ProD6. 
 
4.2.1 Global minimum geometries (GM): 
 
The calculated B3LYP/6-31G(d,p) geometries along with selected bond distances and 
bond angles for the global minimum structures of ProD1GM-6GM are illustrated in 
Figure7. 
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Figure 7: DFT optimized structures for the global minimum (GM) structures in the 
intramolecular proton transfer reaction of tranexamic ProD 1-ProD 6. 
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Examination of the calculated geometries of ProD1GM-6GM (Figure7) indicates that 
ProD1, ProD2 and ProD3 exhibit conformation by which the carboxyl group is engaged 
intramolecular in a hydrogen bond with the neighboring amide oxygen. 
The calculated B3LYP/6-31 G (d,p) intramolecular hydrogen bonding length rGM (O1-H7) 
for these prodrugs was found to be less than 2.90Å for (ProD1, ProD2andProD3). 
Moreover, the hydrogen bond angle α (O1H7O6) was found to be the range of 125.2°-
133.4°. 
After the inspection of the optimized structures forProD4, ProD5 andProD6 in Figure 6 it 
was shown that have rGM values of 3.32Å, 5.95Å and 3.27Å, and the hydrogen bond angle 
α values of 109.6°, 66.2° and 99° respectively. 
4.2.2. Optimized tetrahedral intermediate geometries (INT): 
The calculated properties for the tetrahedral intermediate geometries (ProD1INT-
ProD6INT) are summarized in Table 1 and illustrated in Figure 8. 
 
Figure 8: DFT optimized structures for the tetrahedral intermediate (INT) structures in the 
intramolecular proton transfer reaction of Tranexamic acid ProD 1-ProD 6. 
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4.2.2 Transition state geometries (TS): 
 
The calculated properties for the transition state geometries of (ProD 1TS-ProD 6TS) are 
summarized in Table 1 and illustrated in Figure 9. 
 
 
 
 
 
 
 
 
 
Figure 9: DFT optimized structures for the transition states in the intramolecular proton 
transfer reaction of Tranexamic acid ProD1-ProD 6. 
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4.3 DFT calculations of the kinetic and thermodynamic energies for the proton 
transfer reaction in Tranexamic acid ProD1- ProD6. 
 
The kinetic and thermodynamic properties for the global minimum (GM), intermediate 
(INT) and transition state (TS) structures were calculated using the DFT at B3LYP/6-31 G 
(d,p) level of theory. The enthalpy and entropy energy values for all entities were 
calculated in both; the gas phase and the water phase. The data are shown in table1. 
 
Table 1: DFT (B3LYP) calculated properties for the proton transfer reactions of in 
Tranexamic acid ProD1- ProD6.B3LYP refer to values calculated by B3LYP/6-31G (d, 
p). (GM) and (TS) are global minimumand transition state structures, respectively. 
 
Compound 
B3LYP, Enthalpy, H 
(gas phase) in 
Hartree 
B3LYP (gas phase) 
Entropy, S, 
Cal/Mol-Kelvin 
B3LYP 
Frequency 
Cm
-1
 
TranexamicProD1GM -974.8819081 163.12 ------- 
TranexamicProD1TS -974.8326548 148.66 145.69i 
TranexamicProD2GM -1014.2048171 171.51 ------- 
TranexamicProD2TS -1014.1594626 156.97 115.95i 
TranexamicProD3GM -1053.5140615 179.62 ------- 
TranexamicProD3TS -1053.4868204 171.73 102.39i 
TranexamicProD4GM -1133.3773287 177.52 ------- 
TranexamicProD4TS -1133.3096986 171.68 145.69i 
TranexamicProD5GM         -978.3127626               159.12          ------- 
TranexamicProD5TS         -978.2460971               151.16       -55,1342 
TranexamicProD6GM          -1055.741283               162.53                        ------- 
TranexamicProD6TS         -1055.680604              151.87     -78.2911 
 
Using the calculated DFT values for the enthalpy and entropy of the global minimum 
structures of Tranexamic acid ProD1-ProD6 and their corresponding transition states 
(Table 1) we have calculated the enthalpy activation energies (ΔH‡), entropy activation 
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energies (TΔS‡), and the free activation energies (ΔG‡) in the gas phase and water phase 
for the proton transfer reaction in these processes. The calculated energies are listed in 
Table 2. 
 
 
Table 2: DFT (B3LYP/6-31G (d,p) calculated kinetic and thermodynamic properties for 
the proton transfers in kirby’s 1-7 N-alkylmaleamic acids and in Tranexamic acid ProD1-
ProD 6. 
System 
 
∆H‡ 
(GP) 
TΔS‡ 
(GP) 
∆G‡ 
(GP) 
∆H‡ 
(H2O) 
∆G‡ 
(H2O) 
TranexamicProD1 33.52459878 -2.255715 35.78031378 33.74416208 36.81662708 
TranexamicProD2 27.59055391 -2.220669 29.81122291 30.81535457 33.03602357 
TranexamicProD3 37.73696366 -4.317489 42.05445266 40.88658947 45.20407847 
TranexamicProD4 30.29145232 -3.320757 33.61220932 33.71209667 37.03285367 
TranexamicProD5 41.83280125 -2.363526 44.19632725 38.83264665 42.15340365 
TranexamicProD6 38.07619179 -3.168099 41.24429079 41.04628899 45.36377799 
 
 
 
 
 
 
 
 
 
 
 
43 
 
Table 3:DFT (B3LYP) calculated kinetic and thermodynamic properties for the acid 
catalyzed hydrolysis of 1-7 N-alkylmaleamic acid and Tranexamic acidProD 1- ProD6. 
 
System EsINT EsGM ΔH
‡
 
(GP) 
ΔG‡ 
(GP) 
ΔH‡ 
(H2O) 
ΔG‡ 
(H2O) 
log krel 
(Exp) 
1 20.55 10.16 32.46 33.53 25.01 26.10 0 
2 16.16 10.82 25.67 27.08 16.49 17.90 4.371 
3 17.32 9.40 30.68 32.57 22.91 24.80 1.494 
4 27.89 12.30 41.88 45.37 28.67 32.16 -4.377 
5 19.25 9.18 24.55 26.87 15.57 17.89 2.732 
6 17.59 5.12 30.11 32.12 21.86 23.87 1.516 
7 18.55 6.20 30.76 32.30 22.86 24.40 1.648 
TAProD 1 23.41 14.84 30.91 35.22 19.77 24.08 ----- 
TAProD 2 21.58 15.02 28.46 32.79 16.63 20.99 ----- 
TAProD 3 19.98 14.19 17.09 19.44 7.38 9.73 ----- 
TAProD 4 25.60 19.06 42.44 44.18 23.41 25.15 ----- 
TAProD 5 21.98 15.19 42.13 44.19 38.83 41.83 ----- 
TAProD 6 23.60 16.06 45.36 41.24 41.05 38.07 ----- 
 
 
 
4.3.1. The role of the distance O1-H7 (rGM) and the angle O1H7O6 (α) on the rate of 
the proton transfer in processes Tranexamic acid ProD1- ProD6. 
Careful inspection of Table 2 indicates that the distance between the two reactive 
centers rGM (O1-H7) varies according to the conformation of the global minimum structure 
(GM). Short rGM distance values were achieved when the values of the attack angle (α) in 
the GM conformations were high and close to 180°, whereas small values of α resulted in 
longer rGM distances. In fact when the rGM values were plotted against the corresponding α 
values linear correlation was obtained with R
2
 = 0.968 (Figure 10).  
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Figure 10: Plot of the DFT calculated rGM (Å) vs. angle α (°) for tranexamic acid ProD1-
ProD6, where (rGM) and (α) are the distance between the two reactive centers and the 
attack (hydrogen bond) angle in the GM structure, respectively. 
 
 
In addition, examination of the activation energy values (∆G‡) listed in Table 2 
reveals that the energy needed to execute proton transfer in systems tranexamic acid 
ProD1- ProD6, is largely affected by both the distance between the two reactive centers 
rGM (O1-H7), and the attack angle α (O1H7O6). Systems with low rGM and high α values in 
their global minimum structures, such as (ProD1, ProD2 and ProD3) exhibit much higher 
rates (lower ∆G‡) than these with high rGM and low α values, such as ProD4, ProD5 and 
ProD6 (figure 7).  
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4.3.2The role of the strain energy of the intermediates (EsINT) on the rate of the 
proton transfer in processes Tranexamic acid ProD1- ProD5. 
 
The strain energy values of the intermediates for tranexamic acid ProD1-ProD6 (EsINT) 
were calculated using  llinger’s MM2 method, to examine the role of the (EsINT) on the 
rate of the proton transfer in process tranexamic acid ProD1-ProD6. 
The MM2 strain energies of the intermediates are listed in (Table 3). The calculated MM2 
(EsINT) values for the process tranexamic acid ProD1-ProD6 were examined for 
correlation with the calculated DFT activation free energies (∆G‡), a linear correlation was 
found between ∆G‡ and EsINT with a satisfied correlation coefficient of R
2
=0.694. 
 
 
 
Figure 11: Plot of the DFT calculated ∆G‡ vs. EsINTfor N-alkylmaleamic acid 1-7 and 
tranexamic acidProD1-ProD6. 
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Examination of Figure 11 and Table 3 reveals thatthe rate of a proton transfer in processes 
tranexamic acid ProD1-ProD6is largely dependent on the strain energy of the tetrahedral 
intermediate. Systems having strained tetrahedral intermediates were found to be with low 
rates and vice versa. 
In order to further support this conclusion, the B3LYP 6-31G (d,p)activation energy values 
for 1-7 N-alkylmaleamic acid calculated in water (∆G‡H2O, see Table 3) were examined for 
correlations with log krel and the results are shown in(Figure 12). A linear correlation was 
found between ∆G‡H2Oand log krelwith a correlation coefficient of R
2
= 0.9303. 
 
 
Figure 12: Plot of the DFT calculated ∆G‡vs. relative rate (log krel) in 1-7 N-alkylmaleamic 
4acid. 
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Furthermore, a linear correlation was found between the strain energies for intermediates 
of 1-7 N-alkylmaleamic acid (EsINT) and log krel(Figure 13) with a correlation coefficient of 
R
2
= 0.885. 
 
 
Figure 13: Plot of the EsINT for intermediates of 1-7 N-alkylmaleamic acid vs. relative rate 
(logkrel). 
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Chapter Five: 
_____________________________________________________________ 
Conclusions and future directions  
 
5.1. Conclusions: 
 
Relying on the increased number of documented post-partum hemorrhage (PPH) mortality 
especially in the third world we were encouraged to design a number of Tranexamic acid 
prodrugs using the DFT calculations based on Kirby’s model of acid catalyzed hydrolysis 
of N-alkylmaleamic acids.  
As it is known Tranexamic acid is an amino acid derivative with a low bioavailability and 
short half-life.  Each one of the designed prodrugs has a different linker moiety with a 
potential to provide the drug with a higher bioavailability and a controlled release pattern 
depending solely on intramolecular interactions based on Kirby’s enzyme model (proton 
transfer in N-alkylmaleamic acids). 
Our proposed prodrugs have a carboxylic group as a hydrophilic moiety and a hydrocarbon 
skeleton as a lipophilic moiety, where the combination of both groups ensures a moderate 
hydrophilic lipophilic balance value. 
DFT calculations were made to find prodrug candidates to be used as efficient Tranexamic 
acid delivery systems. The DFT calculation results revealed that the rate of a proton 
transfer in processes Tranexamic acid ProD1-ProD6 is largely dependent on the geometric 
variations of the reactant (GM) mainly the distance between the two reactive centers, rGM, 
and the angle of attack α. It was found that systems with low rGM and high α values in their 
global minimum structures, such as ProD1, ProD2 and ProD3, exhibit much higher rates 
(lower ∆G‡) than these with high rGM and low α values, such as ProD4, ProD5 andProD6. 
 
Moreover, it was found that the rate of a proton transfer in processes Tranexamic ProD1-
ProD6 is largely dependent on the strain energy of the tetrahedral intermediate. Systems 
having strained tetrahedral intermediates were found to be with low rates and vice versa. 
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Therefore, we conclude that the best candidates to fulfill the requirements needed to reach 
better bioavailability than the parent Tranexamicacid are the following: ProD1, 
ProD2andProD3. 
 
 
5.2. Future directions: 
 
 According to the DFT calculations for 1-6 tranexamic acid designed prodrugs. It is 
recommended to synthesize tranexamic acid ProD1, ProD2andProD3 using 
Kirby’s model for further experimental work.  In vitro and in vivo testing should 
follow the synthetic procedure to determine pharmacokinetic and 
pharmacodynamics parameters for each prodrug. 
 In vitro kinetics should be conducted at different pH’s mimicking that of the 
physiological environment.  
 In vivo studies each of these prodrugs should be administered to the animals via IV 
and per os. Samples should be collected and testes routinely.  The concentration of 
Tranexamic acid should be determined by reliable controlled method. 
 Finally, toxicological studies assuring the safety of the prodrug and the released 
linker must also be conducted. 
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Supplementary Material 
 
Content: 
1- Figures of optimized structures of tranexamic acid prodrugs 1-6 GM. 
2- DFT calculated energies for the proton transfers in Tranexamic acid ProD1 –
ProD6. 
3- Xyz Cartesian coordinates for the DFT optimized GM, TS and P in processes 
tranexamic acidProD 1- ProD6. 
 
 
Compound 
B3LYP, Enthalpy, H 
(gas phase) in Hartree 
B3LYP (gas phase) 
Entropy, S, 
Cal/Mol-Kelvin 
B3LYP 
Frequency 
Cm
-1
 
TranexamicProD1GM -974.8819081 163.12 ------- 
Tranexamic ProD1TS -974.8326548 148.66 145.69i 
Tranexamic ProD2GM -1014.2048171 171.51 ------- 
Tranexamic ProD2TS -1014.1594626 156.97 115.95i 
Tranexamic ProD3GM -1053.5140615 179.62 ------- 
Tranexamic ProD3TS -1053.4868204 171.73 102.39i 
Tranexamic ProD4GM -1133.3773287 177.52 ------- 
Tranexamic ProD4TS -1133.3096986 171.68 145.69i 
Tranexamic ProD5GM -978.3127626               159.12 ------- 
Tranexamic ProD5TS -978.2460971               151.16 -55,1342 
Tranexamic ProD6GM -1055.741283 162.53               ------- 
Tranexamic ProD6TS -1055.680604              151.87     -78.2911 
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Optimized GM structures of tranexamicProD1-ProD6. 
Prod 1 GM  
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.535313 
 C     1.429682     0.000000     2.106422 
 C     2.229731    -1.190989     1.553610 
 C     2.228367    -1.228705     0.016916 
 C     0.812419    -1.182718    -0.583682 
 C     1.388292     0.023322     3.645376 
 N     2.689257     0.239468     4.273121 
 C     3.530718    -0.600113     4.933046 
 O     4.583598    -0.129603     5.403692 
 C     0.074014    -2.500981    -0.400805 
 O    -1.113414    -2.501054    -1.057481 
 O     0.456079    -3.461992     0.232694 
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 C     3.151557    -2.030261     5.048040 
 C     3.789644    -3.004457     5.724368 
 C     5.027998    -3.047364     6.589974 
 O     5.297866    -4.107145     7.124070 
 O     5.771780    -1.961301     6.741306 
 H    -0.554598     0.873203     1.901104 
 H    -0.537181    -0.885527     1.905028 
 H     1.921145     0.929763     1.776812 
 H     3.263436    -1.150609     1.914328 
 H     1.795046    -2.126300     1.926041 
 H     2.750560    -2.125514    -0.329012 
 H     2.784612    -0.364999    -0.369685 
 H     0.879309    -1.036192    -1.669462 
 H    -1.023305    -0.023079    -0.384998 
 H     0.455488     0.931123    -0.360158 
 H     0.952216    -0.903267     4.025728 
 H     0.725954     0.831668     3.978861 
 H     3.058942     1.182296     4.238376 
 H    -1.512817    -3.372302    -0.893592 
 H     2.259966    -2.333365     4.510540 
 H     3.348550    -3.996179     5.678448 
 H     5.389989    -1.189465     6.228524 
 H     6.967999    -3.902605     8.205189 
 O     7.757240    -3.853300     8.731657 
 H     7.954932    -4.687087     9.141801 
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Prod 1 INT 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.537591 
 C     1.446839     0.000000     2.085980 
 C     2.286207    -1.142351     1.497802 
 C     2.309152    -1.109465    -0.042047 
 C     0.870840    -1.118947    -0.594334 
 C     3.154172    -2.266988    -0.593342 
 N     3.319864    -2.153530    -2.041842 
 C     4.252454    -3.010039    -2.699825 
 O     5.595386    -2.684720    -2.235634 
 C     6.218184    -3.798549    -1.749060 
 C     5.284820    -4.950778    -1.868633 
 C     4.156415    -4.509088    -2.421474 
 O     4.110916    -2.721130    -4.055910 
 O     7.342796    -3.779617    -1.311433 
 C    -0.822933    -1.150801     2.099120 
 O    -1.429929    -1.984072     1.459966 
 O    -0.837419    -1.142343     3.456482 
 H    -1.393894    -1.893660     3.722779 
 H     2.700705    -3.225210    -0.282295 
 H     0.402545    -2.086619    -0.375711 
 H     1.434054    -0.053459     3.177864 
 H    -0.495994     0.909355     1.903909 
 H     0.379150     0.973424    -0.335584 
 H     2.796345    -0.176209    -0.359247 
 H     4.713354    -3.292181    -4.552952 
 H     2.442488    -2.176851    -2.548974 
 H     4.152359    -2.223001    -0.146239 
 H     3.259788    -5.068544    -2.663141 
 H     5.551959    -5.947949    -1.544948 
 H     1.882430    -2.108403     1.835450 
 H     0.879116    -1.002804    -1.684932 
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 H    -1.024464    -0.092675    -0.372365 
 H     3.309392    -1.082378     1.888146 
 H     1.906306     0.959432     1.817173 
 
 
Prod 1 TS 
 
 C     2.063831    -2.112919    -0.062765  L H 
 O     2.691206    -0.145088    -1.074713  H 
 C     3.241551     0.468723    -0.091243  M H 
 O     3.708920     1.609448    -0.053411  H 
 H     4.339227     3.407917     0.020553  H 
 O     4.582708     4.335612    -0.134624  HH 
 H     4.510614     4.408238    -1.093788  HH 
 C     3.297714    -0.376767     1.173453  H 
 C     2.713152    -1.574705     1.164775  HH 
 H     2.699604    -2.239841     2.026420  H 
 H     3.803429     0.012692     2.052103  H 
 O     2.765415    -2.699373    -1.036033  HH 
 H     3.368235    -1.982226    -1.336004  M H 
 N     0.778762    -2.396614    -0.077791  HH 
 H     0.452282    -2.824190    -0.937524  H 
 C    -0.229342    -1.858695     0.842507  L H 
 H     0.234008    -1.759450     1.826831  H 
 H    -1.025816    -2.606105     0.920873  H 
 C    -0.797021    -0.505396     0.378776  H 
 H     0.050114     0.187891     0.287057  H 
 C    -1.766502     0.037373     1.444347  H 
 H    -1.246622     0.153069     2.403468  H 
 H    -2.570385    -0.694668     1.610729  H 
 C    -2.372439     1.384660     1.026833  H 
 H    -3.069978     1.744780     1.788243  H 
 H    -1.572103     2.130324     0.948619  H 
 O    -5.280076     1.144495     0.548845  HH 
64 
 
 C    -2.134447     0.725417    -1.415239  H 
 O    -4.635178    -0.530831    -0.802502  L H 
 C    -1.489063    -0.604693    -0.992936  H 
 H    -2.264682    -1.379508    -0.959819  M H 
 H    -0.760533    -0.894188    -1.759479  H 
 H    -2.673709     0.586568    -2.356975  H 
 H    -1.346397     1.464852    -1.602406  H 
 H    -6.071159     0.579286     0.557784  HH 
 H    -3.371013     2.323064    -0.632268  H 
 C    -3.080033     1.303700    -0.348856  H 
 C    -4.380804     0.520584    -0.253049  HH 
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PROD 2 GM 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.535313 
 C     1.429682     0.000000     2.106422 
 C     2.229731    -1.190989     1.553610 
 C     2.228367    -1.228705     0.016916 
 C     0.812419    -1.182718    -0.583682 
 C     1.388292     0.023322     3.645376 
 N     2.689257     0.239468     4.273121 
 C     3.530718    -0.600113     4.933046 
 O     4.583598    -0.129603     5.403692 
 C     0.074014    -2.500981    -0.400805 
 O    -1.113414    -2.501054    -1.057481 
 O     0.456079    -3.461992     0.232694 
 C     3.151557    -2.030261     5.048040 
 C     3.789644    -3.004457     5.724368 
 C     5.027998    -3.047364     6.589974 
 O     5.297866    -4.107145     7.124070 
 O     5.771780    -1.961301     6.741306 
 H    -0.554598     0.873203     1.901104 
 H    -0.537181    -0.885527     1.905028 
 H     1.921145     0.929763     1.776812 
 H     3.263436    -1.150609     1.914328 
 H     1.795046    -2.126300     1.926041 
 H     2.750560    -2.125514    -0.329012 
 H     2.784612    -0.364999    -0.369685 
 H     0.879309    -1.036192    -1.669462 
 H    -1.023305    -0.023079    -0.384998 
 H     0.455488     0.931123    -0.360158 
 H     0.952216    -0.903267     4.025728 
 H     0.725954     0.831668     3.978861 
 H     3.058942     1.182296     4.238376 
 H    -1.512817    -3.372302    -0.893592 
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 H     2.259966    -2.333365     4.510540 
 C     3.176541    -4.382909     5.660541 
 H     5.389989    -1.189465     6.228524 
 H     6.967999    -3.902605     8.205189 
 O     7.757240    -3.853300     8.731657 
 H     7.954932    -4.687087     9.141801 
 H     3.781080    -5.076415     6.243210 
 H     2.167156    -4.350467     6.067985 
 H     3.139222    -4.715976     4.624397 
 
 
 
PROD 2 INT 
 
 C    -2.886507     0.287352    -1.258472 
 C    -2.680121    -0.982066    -0.470897 
 O    -3.234890    -0.757369     0.793133 
 C    -3.786352     0.545613     0.831875 
 C    -3.563064     1.169983    -0.513157 
 N    -1.202985    -1.329392    -0.234872 
 C    -0.343608    -0.315893     0.490788 
 C     1.097373    -0.812386     0.647884 
 C     1.885788     0.251048     1.443983 
 C     3.361757    -0.138491     1.604948 
 C     4.054066    -0.398054     0.242935 
 C     3.260705    -1.446384    -0.562122 
 C     1.768415    -1.102843    -0.710947 
 C     4.210844     0.913331    -0.511457 
 O     5.421995     1.462815    -0.307570 
 O    -3.114510    -2.152101    -1.060762 
 O    -4.309163     0.978072     1.809508 
 C    -4.077097     2.533424    -0.816055 
 O     3.352755     1.446936    -1.190224 
 H     5.440829     2.309570    -0.787620 
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 H    -0.381839     0.601722    -0.100811 
 H     1.674780    -0.221645    -1.354385 
 H     3.893933     0.641461     2.158188 
 H     5.059490    -0.781642     0.436980 
 H     3.362637    -2.408106    -0.044106 
 H     1.081513    -1.737289     1.246796 
 H    -4.066417    -2.101669    -1.238329 
 H    -0.786456    -1.553896    -1.145237 
 H    -0.826575    -0.144800     1.454307 
 H    -2.570950     0.383210    -2.291028 
 H     1.818285     1.211544     0.919426 
 H     1.282332    -1.949832    -1.219761 
 H     3.701015    -1.579194    -1.555098 
 H     1.432045     0.387914     2.432393 
 H     3.439351    -1.055047     2.202682 
 H    -3.682993     3.254048    -0.091869 
 H    -3.807684     2.851925    -1.823880 
 H    -5.167286     2.556050    -0.712859 
 H    -1.217796    -2.213200     0.289793 
 
 
PROD 2 TS 
 
 N     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.842000 
 O     1.391148     0.000000     2.301836 
 C     1.599821     1.033149     3.162485 
 O     2.666971     1.246591     3.689311 
 H     4.415473     1.513955     4.476686 
 O     5.153434     1.829187     5.019732 
 H     5.226481     2.763766     4.793623 
 C     0.330776     1.806465     3.327598 
 C    -0.586320     1.208154     2.562674 
 C     0.264962     3.004273     4.214538 
68 
 
 H    -0.741322     3.427146     4.238745 
 H     0.565210     2.740117     5.234349 
 H     0.969324     3.773569     3.881038 
 H    -1.626524     1.484476     2.429772 
 O    -0.645185    -1.183012     2.193749 
 H    -0.924860    -0.260698    -0.323528 
 C     0.537082     1.168023    -0.697059 
 H    -0.106829     2.060263    -0.600296 
 H     1.498282     1.412701    -0.233521 
 C     0.764135     0.871804    -2.186318 
 C    -0.543373     0.513916    -2.917417 
 C    -0.338750     0.291375    -4.426442 
 C     0.410698     1.435670    -5.132930 
 C     1.711025     1.792978    -4.361488 
 C     1.446686     2.067711    -2.875781 
 C    -0.429184     2.688966    -5.300785 
 O     0.136048     3.544362    -6.190571 
 H     0.699372     1.122474    -6.142893 
 H     0.249008    -0.623601    -4.578346 
 H    -1.307974     0.124254    -4.908621 
 H    -0.973522    -0.402038    -2.493842 
 H    -1.270856     1.320443    -2.775890 
 H     1.443178     0.008330    -2.242656 
 H     0.812251     2.959105    -2.767894 
 H     2.395054     2.298593    -2.375016 
 H     2.200772     2.649314    -4.837026 
 H     2.398198     0.942747    -4.456622 
 H    -0.776034    -1.183178     3.152735 
 O    -1.454757     2.964969    -4.712518 
 H    -0.426831     4.337309    -6.196874 
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PROD 3 GM 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.546682 
 C     1.422992     0.000000     2.123255 
 C     2.256014     1.180194     1.588317 
 C     2.272776     1.176121     0.050277 
 C     0.857186     1.153606    -0.548116 
 C     3.664194     1.154059     2.201786 
 N     4.446074     2.344634     1.862699 
 C     5.779665     2.445578     1.641955 
 C     6.552549     1.205109     1.272833 
 C     6.109093     0.511682    -0.001455 
 C     0.438661    -1.344788    -0.564080 
 O     1.352133    -1.538031    -1.338236 
 O     6.336798     3.555947     1.681509 
 O    -0.342757    -2.356737    -0.111034 
 C     7.620672     0.762511     1.974543 
 C     8.359471    -0.491598     1.568049 
 C     8.150708     1.389315     3.246704 
 O     8.087651     2.710349     3.406620 
 O     8.664760     0.690400     4.105163 
 H     1.375699     0.035165     3.218492 
 H     1.926833    -0.943006     1.865472 
 H     1.765023     2.108506     1.925365 
 H     2.812939     2.054704    -0.319902 
 H     2.817340     0.293076    -0.304170 
 H     0.919500     1.085755    -1.638014 
 H     0.344327     2.094971    -0.312381 
 H    -1.038851     0.124740    -0.333941 
 H    -0.566741    -0.856144     1.922065 
 H    -0.524543     0.903197     1.883059 
 H     4.210765     0.270684     1.863608 
 H     3.582920     1.075709     3.294976 
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 H     4.029652     3.239115     2.099099 
 H    -0.004963    -3.167045    -0.528965 
 H     7.626828     3.160181     2.652051 
 H     8.877823    -0.905308     2.432675 
 H     7.689080    -1.251356     1.159173 
 H     9.108122    -0.265237     0.796947 
 H     6.966061     0.337957    -0.658874 
 H     5.650192    -0.465846     0.197727 
 H     5.381262     1.109932    -0.551289 
 
 
 
 PROD 3 INT 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.540913 
 C     1.452036     0.000000     2.086206 
 C     2.295849    -1.131107     1.485290 
 C     2.333428    -1.060662    -0.052525 
 C     0.900068    -1.087026    -0.617158 
 C     3.205913    -2.188478    -0.620712 
 N     3.390689    -2.042109    -2.062026 
 C     4.343975    -2.884855    -2.710538 
 O     5.674507    -2.508645    -2.260763 
 C     6.331193    -3.607763    -1.792545 
 C     5.443929    -4.798006    -1.890932 
 C     4.282782    -4.390345    -2.424684 
 O     4.194427    -2.613634    -4.074444 
 O     7.469828    -3.564677    -1.387070 
 C     5.904873    -6.140153    -1.415122 
 C     3.046599    -5.162928    -2.744441 
 C    -0.786755    -1.165045     2.116955 
 O    -1.099559    -2.187403     1.541981 
 O    -1.112548    -0.949071     3.416935 
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 H    -1.585880    -1.745942     3.710837 
 H     2.765880    -3.161453    -0.333878 
 H     0.452871    -2.068644    -0.423404 
 H     1.439538    -0.060799     3.178665 
 H    -0.494362     0.908417     1.905989 
 H     0.351239     0.987102    -0.326472 
 H     2.805777    -0.110514    -0.342088 
 H     4.842307    -3.146650    -4.556471 
 H     2.521725    -2.053185    -2.583039 
 H     4.196991    -2.138285    -0.157727 
 H     1.889265    -2.104444     1.794935 
 H     0.914925    -0.940990    -1.704751 
 H    -1.023254    -0.109914    -0.374475 
 H     3.315380    -1.076976     1.886397 
 H     1.904058     0.965509     1.826346 
 H     6.989669    -6.216198    -1.519301 
 H     5.675054    -6.281431    -0.352360 
 H     5.428268    -6.954688    -1.967582 
 H     2.743247    -4.979276    -3.780995 
 H     3.186865    -6.236173    -2.599648 
 H     2.211969    -4.842570    -2.107546 
 H     3.828260    -1.213016    -2.432429 
 
 
PROD 4 GM 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.530091 
 C     1.422978     0.000000     2.100567 
 C     2.421792    -0.969736     1.455721 
 C     2.325392    -0.891044    -0.065445 
 C     0.910678    -1.064770    -0.574775 
 C    -0.720255     1.257805     2.022456 
 C    -0.767899    -1.200667     2.042967 
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 O    -1.209611    -2.169570     1.420228 
 C     3.836794    -0.546541     1.870101 
 C     2.239185    -2.373159     2.064975 
 O     2.106267    -2.498825     3.298316 
 O    -1.018577    -1.178869     3.380270 
 N     2.360971    -3.490479     1.254376 
 C     2.222337    -4.825220     1.779843 
 C     0.960101    -5.541545     1.379734 
 C     0.096925    -6.032072     2.365072 
 C    -1.055998    -6.726705     2.005167 
 C    -1.354455    -6.928925     0.650769 
 C    -0.493898    -6.437046    -0.338451 
 C     0.660518    -5.749292     0.028613 
 C    -2.580764    -7.655384     0.302079 
 O    -3.426789    -8.147084     1.055851 
 O    -2.813236    -7.807410    -1.034433 
 H    -1.741462    -7.116615     2.774307 
 H    -0.737066    -6.596892    -1.400261 
 H     0.323913    -5.863610     3.428409 
 H     1.338238    -5.371702    -0.750257 
 H    -3.645343    -8.289541    -1.160328 
 H     2.294123    -4.780826     2.904895 
 H     3.096744    -5.429717     1.396907 
 H     2.185895    -3.385632     0.283015 
 H     1.367663    -0.217033     3.201465 
 H     1.832148     1.037582     1.972737 
 H     3.011587    -1.633074    -0.546468 
 H     2.694442     0.124420    -0.375393 
 H     0.506538    -2.074809    -0.303088 
 H    -1.045930    -0.167437    -0.365452 
 H     0.332454     1.010393    -0.352809 
 H     3.934108    -0.585290     2.981124 
 H     4.044066     0.492398     1.522835 
 H     4.588995    -1.232951     1.416245 
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 H    -0.747027     1.270698     3.137847 
 H    -1.766029     1.275839     1.636378 
 H    -0.188582     2.168220     1.659947 
 H    -1.469306    -1.997857     3.639679 
 H     0.907217    -0.989980    -1.692918 
 
 
PROD 4 INT 
 
 C    -2.907562    -0.166880    -0.951316 
 C    -2.230129    -1.133319     0.104989 
 O    -2.465120    -0.635013     1.370491 
 C    -3.065780     0.656605     1.340640 
 C    -3.176816     1.143715    -0.098149 
 N    -0.655764    -1.304001    -0.050051 
 C     0.296019    -0.435101     0.740300 
 C     1.738327    -0.945269     0.640495 
 C     2.258696    -0.976026    -0.811821 
 C     3.752128    -1.336893    -0.886884 
 C     4.643215    -0.447099     0.003280 
 C     4.105043    -0.448089     1.456392 
 C     2.624926    -0.050341     1.534723 
 C     4.730210     0.980847    -0.512355 
 O     5.972949     1.482024    -0.388725 
 O    -2.621062    -2.460581     0.020145 
 O    -3.365307     1.183090     2.363031 
 C    -4.565722     1.789259    -0.294022 
 C    -2.127861     2.271947    -0.281304 
 C    -4.226826    -0.843261    -1.391099 
 C    -2.059965     0.064051    -2.213903 
 O     3.800161     1.631422    -0.952787 
 H     2.283839    -0.110956     2.574686 
 H     2.513462     0.992803     1.217068 
 H     1.768148    -1.967714     1.052718 
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 H     1.704118    -1.712393    -1.412638 
 H     2.112867     0.009612    -1.266982 
 H     4.084363    -1.291224    -1.928593 
 H     3.891098    -2.374849    -0.559715 
 H     5.658995    -0.851353     0.011317 
 H     4.702495     0.222272     2.082357 
 H     4.239872    -1.458056     1.863165 
 H     0.218495     0.577583     0.341170 
 H    -0.065420    -0.437955     1.769100 
 H    -0.418305    -1.257777    -1.044591 
 H     5.946071     2.402932    -0.703535 
 H    -3.220846    -2.651074     0.758296 
 H    -4.657397     2.645487     0.377321 
 H    -5.388671     1.108785    -0.073042 
 H    -4.675583     2.148793    -1.320704 
 H    -4.885156    -1.073794    -0.549572 
 H    -4.021096    -1.777320    -1.915072 
 H    -4.769311    -0.182665    -2.069427 
 H    -1.093708     0.540591    -2.022746 
 H    -2.597678     0.720393    -2.902869 
 H    -1.897192    -0.876770    -2.752493 
 H    -2.314444     3.057572     0.453983 
 H    -2.221463     2.710949    -1.277413 
 H    -1.094914     1.943237    -0.154663 
 H    -0.512686    -2.281512     0.226184 
 
 
PROD 4 TS  
 
 O     2.243827     1.794144     0.142161 
 C     1.994335    -0.082364    -1.164158 
 C     2.416731    -1.412053    -0.387818 
 C     2.853946    -0.901521     1.016690 
 C     2.880869     0.612331     0.871258 
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 N     0.605067     0.059765    -1.598710 
 C    -0.295411     0.693722    -0.659593 
 C    -1.773612     0.606669    -1.072339 
 C    -2.581373     1.520476    -0.156910 
 C    -4.055859     1.474902    -0.503114 
 C    -4.617197     0.056660    -0.453748 
 C    -3.775051    -0.895736    -1.294286 
 C    -2.296129    -0.819711    -0.966781 
 C    -4.710967    -0.414403     0.972949 
 O    -5.975035    -0.353664     1.479702 
 O     2.863186     0.080322    -2.260231 
 C     3.559624    -2.086377    -1.137499 
 C     1.278309    -2.415646    -0.308393 
 C     4.231740    -1.383285     1.447274 
 C     1.862655    -1.238925     2.125683 
 O     3.261686     1.492346     1.630774 
 O    -3.840991    -0.834282     1.739266 
 H    -2.209924     2.572642    -0.249578 
 H    -2.438709     1.195469     0.907535 
 H    -1.887749     0.962364    -2.132223 
 H    -1.740137    -1.490006    -1.670847 
 H    -2.127833    -1.199362     0.076229 
 H    -4.135054    -1.945534    -1.142617 
 H    -3.931885    -0.633339    -2.373036 
 H    -5.664546     0.073424    -0.870820 
 H    -4.629841     2.128682     0.202321 
 H    -4.210590     1.872351    -1.539850 
 H    -0.193176     0.259118     0.377808 
 H     0.004308     1.778426    -0.599616 
 H     0.262183    -0.818549    -1.928618 
 H    -5.976140    -0.655530     2.401133 
 H     2.680766     0.936982    -2.669959 
 H     4.480968    -0.942945     2.443578 
 H     5.018481    -1.067014     0.723613 
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 H     4.237944    -2.494862     1.532497 
 H     4.425627    -1.393547    -1.255751 
 H     3.215181    -2.375879    -2.159468 
 H     3.889251    -3.003240    -0.595677 
 H     0.358250    -1.984401     0.152957 
 H     1.599809    -3.291837     0.305113 
 H     1.022989    -2.789206    -1.330041 
 H     2.197252    -0.758643     3.077516 
 H     1.817022    -2.341927     2.280195 
 H     0.841395    -0.861116     1.885585 
 H     2.995068     3.277650     0.769608 
 O     2.887359     4.146754     0.401428 
 H     2.507703     4.078078    -0.466699 
 
 
PROD 5 GM   
 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.520475 
 C     1.411278     0.000000     2.083318 
 C     2.397741    -0.686102     1.141259 
 C     1.724685    -1.814605     0.370781 
 C     0.631710    -1.281181    -0.538038 
 C     3.581477    -1.209942     1.906654 
 O     3.297407    -2.161597     2.839212 
 C    -1.428071     0.120672    -0.565635 
 N    -2.054413     1.399254    -0.368241 
 C    -2.254435     2.293822    -1.399374 
 O    -2.024817     1.989107    -2.586020 
 O     4.767421    -0.892201     1.795599 
 C    -2.788741     3.675936    -1.047067 
 C    -4.270694     3.683137    -0.667574 
 C    -5.080630     2.801119    -1.609317 
77 
 
 C    -4.448312     3.206747     0.758974 
 O    -3.591872     2.973125     1.617982 
 C    -4.788877     5.120325    -0.738585 
 O    -5.741831     3.044111     1.145504 
 H    -0.548780    -0.907489     1.883835 
 H    -0.544940     0.897249     1.910178 
 H     1.752901     1.052314     2.257700 
 H     1.409614    -0.522484     3.075017 
 H     2.795429     0.069259     0.406069 
 H     1.294756    -2.542851     1.106530 
 H     2.486705    -2.362751    -0.239714 
 H    -0.152781    -2.072878    -0.657442 
 H     1.050737    -1.074898    -1.556462 
 H     0.611068     0.874774    -0.355090 
 H    -1.392884    -0.096228    -1.671389 
 H    -2.072656    -0.660497    -0.070396 
 H    -2.137033     1.725538     0.567629 
 H     4.115979    -2.440706     3.278399 
 H    -2.185853     4.116151    -0.211017 
 H    -2.651166     4.317957    -1.957163 
 H    -5.771740     2.751941     2.070727 
 H    -4.170275     5.789583    -0.096458 
 H    -5.848426     5.159465    -0.390975 
 H    -4.741123     5.484113    -1.791761 
 H    -4.943891     3.153059    -2.659177 
 H    -6.162506     2.849560    -1.341304 
 H    -4.739670     1.740810    -1.544545 
 
 
 
 
 
 
 
78 
 
 PROD 5 INT   
 
 O     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.463508 
 C     1.490186     0.000000     1.923430 
 C     2.323765    -0.054894     0.633151 
 C     1.288175    -0.016192    -0.481898 
 N    -0.822115    -1.074668     2.001158 
 C    -0.478839    -2.405431     1.535899 
 C    -1.450920    -3.483530     2.040351 
 C    -2.855036    -3.267364     1.485617 
 C    -3.626890    -4.568104     1.347642 
 C    -3.209627    -5.566298     2.422334 
 C    -1.745598    -5.968899     2.262043 
 C    -0.919742    -4.854497     1.644409 
 C    -4.093389    -6.781073     2.343744 
 O    -5.113450    -6.779355     3.246602 
 O    -0.530798     1.273185     1.750644 
 C     3.249867     1.143222     0.514772 
 C     3.118153    -1.347145     0.538646 
 O     1.402923    -0.002494    -1.698963 
 O    -4.030067    -7.755035     1.591134 
 H    -3.411961    -2.572185     2.165643 
 H    -2.799351    -2.776705     0.479337 
 H    -3.437797    -5.019715     0.339528 
 H    -4.725086    -4.364561     1.428367 
 H    -3.358106    -5.088864     3.431128 
 H    -1.671550    -6.882867     1.616013 
 H    -1.333388    -6.234926     3.268944 
 H    -0.936348    -4.946122     0.527544 
 H     0.145673    -4.959548     1.973473 
 H    -1.496014    -3.435208     3.163562 
 H    -0.437707    -2.456966     0.409072 
 H     0.551990    -2.642233     1.924159 
79 
 
 H    -1.794252    -0.878750     1.863747 
 H    -5.649731    -7.579924     3.137882 
 H     1.709135    -0.865690     2.590935 
 H     1.680779     0.943040     2.492542 
 H     2.671000     2.094481     0.582415 
 H     3.782183     1.115938    -0.465825 
 H     4.002869     1.120656     1.337207 
 H     3.886700    -1.379309     1.346106 
 H     3.629760    -1.408157    -0.451400 
 H     2.443551    -2.229357     0.648962 
 H    -1.317307     1.410810     1.206182 
 
 
PROD 5 TS  
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.537051 
 C     1.462100     0.000000     2.059436 
 C     2.458438     0.673754     1.089200 
 C     1.780970     1.827046     0.312066 
 C     0.629185     1.289994    -0.568281 
 C    -0.811988    -1.172810     2.098643 
 N    -0.911446    -1.101314     3.560767 
 C    -1.990814    -2.323042     4.418270 
 O    -1.766904    -3.682404     3.906858 
 C    -2.941306    -4.385851     3.845173 
 C    -4.126110    -3.494597     4.246683 
 C    -3.496561    -2.088181     4.250530 
 O    -1.680331    -2.343574     5.787493 
 C    -4.586976    -3.932660     5.655198 
 C    -5.270214    -3.657931     3.236869 
 O    -2.976121    -5.544698     3.520141 
 C     2.817843     2.568148    -0.512372 
 O     3.033499     2.425230    -1.696391 
80 
 
 O     3.543743     3.421744     0.254680 
 H     1.501978     0.506874     3.030845 
 H     1.791903    -1.034047     2.229802 
 H     2.833168    -0.056629     0.362492 
 H     3.328241     1.045971     1.638528 
 H     1.401083     2.541749     1.051873 
 H     1.014485     1.109694    -1.575653 
 H    -0.138096     2.067218    -0.659934 
 H     0.553298    -0.878777    -0.356798 
 H    -1.020877    -0.108460    -0.384022 
 H    -0.491119     0.921792     1.878088 
 H    -0.371709    -2.123493     1.757645 
 H    -1.825703    -1.131573     1.684436 
 H     0.008498    -1.118085     3.990734 
 H     4.206711     3.816647    -0.336862 
 H    -3.680905    -1.580449     3.300113 
 H    -3.853763    -1.439682     5.052597 
 H    -3.792579    -3.788072     6.391411 
 H    -4.877365    -4.986981     5.650064 
 H    -5.451879    -3.336261     5.964036 
 H    -6.127598    -3.043902     3.530855 
 H    -5.588645    -4.702572     3.191449 
 H    -4.963680    -3.355046     2.230263 
 H    -0.921606    -2.936048     5.895250 
 
 
PROD 6 GM  
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.521641 
 C     1.418529     0.000000     2.059187 
 C     2.192950    -1.201972     1.526089 
 C     2.179319    -1.230529     0.000237 
 C     0.758654    -1.206468    -0.530194 
81 
 
 C     3.616812    -1.129108     2.006314 
 O     4.451851    -0.235756     1.851297 
 C    -1.423231     0.083733    -0.578768 
 N    -2.354184    -0.912514    -0.138753 
 C    -2.754868    -2.032085    -0.842983 
 O    -3.476795    -2.863282    -0.256583 
 C    -2.384675    -2.200607    -2.315548 
 C    -3.317160    -1.318581    -3.142928 
 C    -3.081546    -1.493876    -4.629378 
 C    -3.242415    -2.945980    -5.033177 
 C    -2.305159    -3.831450    -4.238653 
 C    -2.526412    -3.666249    -2.735171 
 C    -1.564383    -4.584616    -2.030554 
 O    -1.659565    -5.802407    -1.870200 
 O     4.021156    -2.221479     2.711569 
 O    -0.430182    -4.003898    -1.544081 
 H    -3.160363    -0.245462    -2.862269 
 H    -4.379492    -1.581402    -2.898293 
 H    -1.314238    -1.893707    -2.475503 
 H    -3.562977    -4.018187    -2.461305 
 H    -1.243193    -3.573489    -4.486803 
 H    -2.470319    -4.905444    -4.512862 
 H    -4.301700    -3.269137    -4.862805 
 H    -3.024787    -3.061775    -6.125603 
 H    -3.810263    -0.860837    -5.197331 
 H    -2.051020    -1.142032    -4.893071 
 H    -2.571208    -0.907266     0.833334 
 H    -1.345628     0.062607    -1.701176 
 H    -1.848322     1.087886    -0.283435 
 H     4.943851    -2.111290     2.988917 
 H     0.115515    -4.675866    -1.106389 
 H    -0.536491    -0.904466     1.908368 
 H    -0.541407     0.905194     1.897816 
 H     1.945490     0.941813     1.756699 
82 
 
 H     1.396523    -0.035633     3.178154 
 H     1.726000    -2.147594     1.917972 
 H     2.697798    -2.155554    -0.359599 
 H     2.747824    -0.346008    -0.388476 
 H     0.785053    -1.173142    -1.650105 
 H     0.227565    -2.151067    -0.240938 
 H     0.531518     0.930149    -0.350046 
 
 
PROD 6 INT 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.524287 
 C     1.413947     0.000000     2.071557 
 C     2.195993    -1.197523     1.539488 
 C     2.204721    -1.199536     0.014618 
 C     0.789883    -1.187661    -0.530677 
 C     3.607680    -1.138636     2.054042 
 O     4.531455    -0.386571     1.738607 
 C    -1.456385    -0.040045    -0.495953 
 N    -1.585593     0.138616    -1.929857 
 C    -1.777105     1.501304    -2.406225 
 C    -1.675766     1.652078    -3.958632 
 C    -0.180688     1.981992    -4.141856 
 C     0.137211     2.750203    -2.888051 
 O    -0.755549     2.399992    -1.880544 
 C     0.027914     2.593174    -5.506465 
 C    -0.399381     1.561005    -6.545783 
 C    -1.799087     1.008170    -6.319343 
 C    -2.043791     0.524932    -4.891791 
 O    -2.967150     2.125849    -1.969066 
 O     0.996348     3.556930    -2.571746 
 O     3.885297    -2.064918     3.014593 
 H    -3.119972     0.246720    -4.764233 
83 
 
 H    -1.425570    -0.384717    -4.683687 
 H    -2.302512     2.550644    -4.217312 
 H     0.425469     1.031609    -4.076331 
 H    -0.578115     3.527557    -5.615219 
 H     1.103371     2.864670    -5.654217 
 H     0.334102     0.713310    -6.533253 
 H    -0.354433     2.029823    -7.562044 
 H    -1.970411     0.155620    -7.025196 
 H    -2.549970     1.803607    -6.564491 
 H    -2.319149    -0.429674    -2.304300 
 H    -2.035901     0.748911     0.064647 
 H    -1.892783    -1.041452    -0.221864 
 H     4.804944    -1.969524     3.306370 
 H    -2.810141     2.516882    -1.099732 
 H    -0.549435    -0.901288     1.899858 
 H    -0.538136     0.907436     1.900683 
 H     1.937338     0.945192     1.773333 
 H     1.384789    -0.039482     3.190068 
 H     1.717903    -2.145282     1.911946 
 H     2.742235    -2.109385    -0.355192 
 H     2.764959    -0.299739    -0.350461 
 H     0.829754    -1.144017    -1.648878 
 H     0.269634    -2.138710    -0.246624 
 H     0.482821     0.950579    -0.360204 
 
 
 
 PROD 6 TS 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.538835 
 C     1.417807     0.000000     2.126516 
 C     2.260199    -1.159103     1.576228 
 C     2.278193    -1.144839     0.028588 
84 
 
 C     0.852185    -1.162729    -0.535840 
 C     3.670563    -1.131954     2.132322 
 O     4.174590    -0.230617     2.766264 
 C    -1.436235    -0.046817    -0.542738 
 N    -1.510847     0.072907    -2.012414 
 C    -2.119852     1.670034    -2.698899 
 C    -1.896676     1.790003    -4.211877 
 C    -0.433407     2.231274    -4.269040 
 C    -0.323189     3.124617    -3.049915 
 O    -1.288070     2.729796    -2.146755 
 C    -0.043539     2.755079    -5.645720 
 C    -0.322897     1.639562    -6.676187 
 C    -1.759213     1.080457    -6.590782 
 C    -2.155667     0.628296    -5.166809 
 O    -3.456072     1.974399    -2.412070 
 O     0.445650     4.017352    -2.812155 
 O     4.353493    -2.266643     1.825840 
 H    -3.208161     0.322458    -5.148607 
 H    -1.551733    -0.239693    -4.870074 
 H    -2.523572     2.637849    -4.519033 
 H     0.186946     1.352182    -4.033446 
 H    -0.633911     3.649359    -5.883204 
 H     1.009460     3.053133    -5.668329 
 H     0.389948     0.820342    -6.506939 
 H    -0.133671     2.008829    -7.690291 
 H    -1.870720     0.244945    -7.290958 
 H    -2.465697     1.855284    -6.918580 
 H    -2.081092    -0.668732    -2.404197 
 H    -2.023970     0.737342    -0.042200 
 H    -1.894517    -1.000577    -0.252226 
 H     5.243054    -2.150490     2.200457 
 H    -3.555138     2.038289    -1.451285 
 H    -0.542453    -0.888611     1.897560 
 H    -0.551819     0.870638     1.914323 
85 
 
 H     1.922206     0.943313     1.886469 
 H     1.377936    -0.052893     3.219551 
 H     1.819556    -2.116758     1.889702 
 H     2.850439    -2.000113    -0.343553 
 H     2.797281    -0.238517    -0.311621 
 H     0.877063    -1.125935    -1.629757 
 H     0.371102    -2.115357    -0.263681 
 H     0.449782     0.942218    -0.341370 
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 الحسابيت بالطرقك حمض الترانيكساميمن مبتكرة أدويتطلائع  تصميم
 
  مريم مأمون محمد بدر: إعداد
 رفيق قرمان أ.دإشراف: 
 الملخص:
 )p,d( G13-6 PYL3B عهً انًستىي   latibro ralucelom TFDانطشق انذسابيت  باستخذاو
نعًهيت َقم انبشوتىٌ ضًٍ جضئي في عذد يٍ ًَارج الإَضيًههعانى كيشبي واستغلال  2MMودساباث 
هزِ انًُارج نتصًيى أدويت  يقذيت نذًض انتشاَيكساييك انتي لا تعتًذ عهً اَضيًاث نتفعيهها و تًتاص 
 ع انذواء الأو.بفاعهيت أطىل  رو يقاسَت ي
أٌ انقىة انذافعت نُقم انبشوتىٌ   gurdorpنقذ وجذ أٌ يعذل انتذىيم انذاخهي نذًض انتشاَيكساييك
ديث وجذ اٌ الاَظًت  α ،وصاويتانهجىو MGrتعتًذ بشكم كايم عهً انًسافت بيٍ انًشكضيٍ انًتفاعهيٍ 
في هياكهها تظهش 3DorP-1DorPانًشتفعت يثم  α) وقيى انضاويت MGrراث انًسافت انًُخفضت (
يُخفضت يثم  α) و قيًت انضاويت MGr) يٍ تهك انتي نها يسافت يشتفعت  (G∆‡يعذلاث اعهً بكثيش (أقم
 .6DorP-4DorP
 
يتأثش بشكم كبيش   gurdorpنقذ وجذ أٌ يعذل انتذىيم انذاخهي نذًض انتشاَيكساييكعلاوة عهً رنك،
اعهً يكىٌ يعذل انتذىيم  niarts، ديث اٌ يٍ تًهك انًتىسطتنكم يٍ سباعيت الاسطىح niartsبقىة 
 ، وانعكس صذيخ.انذاخهي أقم 
 
